Thyroid hormone replacement therapy for subclinical hypothyroidism in adults: systematic review and meta-analysis of randomized-controlled trials

2018 ◽  
Author(s):  
Marieke Snel ◽  
Martin Feller ◽  
Elisavet Moutzouri ◽  
Ian Ford ◽  
Jacobijn Gussekloo ◽  
...  
2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Gulbanu Erkan ◽  
Aycan Fahri Erkan ◽  
Mustafa Cemri ◽  
Selma Karaahmetoglu ◽  
Mustafa Cesur ◽  
...  

Background. Subclinical hypothyroidism (SH) predominantly affects women. The necessity of treatment in SH is controversial.Objective. We aimed to investigate the response of diastolic dysfunction to thyroid hormone replacement therapy (THRT) in women.Methods and Results. Twenty-two female subjects with SH and 20 euthyroid female controls were enrolled. Baseline and follow-up biochemical, hormonal, and echocardiographic evaluations were performed. Repeat echocardiograms were performed three months after the achievement of a euthyroid status with THRT. Mean baseline myocardial performance index (MPI) was0.27±0.08in the SH group, and0.22±0.06in the control group (P=0.03). MPI did not change significantly after THRT. Pulsed-wave Doppler findings were not different among the groups. However, tissue Doppler-derived mitral annular E’ velocities were significantly lower in the SH group. A moderate but significant improvement was observed in E’ velocities after THRT (13.2±3.87versus14.53±2.75,P=0.04). We also observed left ventricular concentric remodeling in SH patients which was reversible with THRT.Conclusions. Tissue Doppler echocardiography may be a useful tool for monitoring the response of diastolic dysfunction to thyroid hormone replacement therapy in patients with SH. Our findings suggest that THRT may reverse diastolic dysfunction in women with SH.


2012 ◽  
Vol 97 (8) ◽  
pp. 2732-2740 ◽  
Author(s):  
Dong Ho Shin ◽  
Mi Jung Lee ◽  
Seung Jun Kim ◽  
Hyung Jung Oh ◽  
Hyoung Rae Kim ◽  
...  

Abstract Context: Subclinical hypothyroidism is not a rare condition, but the use of thyroid hormone to treat subclinical hypothyroidism is an issue of debate. Objective: This study was undertaken to investigate the impact of thyroid hormone therapy on the changes in estimated glomerular filtration rate (eGFR) in subclinical hypothyroidism patients with stage 2–4 chronic kidney disease. Patients: A total of 309 patients were included in the final analysis. Main Outcome Measure: The changes in eGFR over time were compared between patients with and without thyroid hormone replacement therapy using a linear mixed model. Kaplan-Meier curves were constructed to determine the effect of thyroid hormone on renal outcome, a reduction of eGFR by 50%, or end-stage renal disease. The independent prognostic value of subclinical hypothyroidism treatment for renal outcome was ascertained by multivariate Cox regression analysis. Results: Among the 309 patients, 180 (58.3%) took thyroid hormone (treatment group), whereas 129 (41.7%) did not (nontreatment group). During the mean follow-up duration of 34.8 ± 24.3 months, the overall rate of decline in eGFR was significantly greater in the nontreatment group compared to the treatment group (−5.93 ± 1.65 vs. −2.11 ± 1.12 ml/min/yr/1.73 m2; P = 0.04). Moreover, a linear mixed model revealed that there was a significant difference in the rates of eGFR decline over time between the two groups (P < 0.01). Kaplan-Meier analysis also showed that renal event-free survival was significantly lower in the nontreatment group (P < 0.01). In multivariate Cox regression analysis, thyroid hormone replacement therapy was found to be an independent predictor of renal outcome (hazard ratio, 0.28; 95% CI, 0.12–0.68; P = 0.01). Conclusion: Thyroid hormone therapy not only preserved renal function better, but was also an independent predictor of renal outcome in chronic kidney disease patients with subclinical hypothyroidism.


2014 ◽  
Vol 11 (1) ◽  
pp. 33-38 ◽  
Author(s):  
Prahlad Karki ◽  
Ila Pandey ◽  
Sangita Bhandary ◽  
Madhab Lamsal ◽  
Nikesh Raj Shrestha

Background & Aims: Diastolic dysfunction is the common condition with Subclinical Hypothyroidism and is reversible in many cases after treatment. We aimed to investigate the response of diastolic dysfunction to thyroid hormone replacement therapy in patients of Subclinical Hypothyroidism. Methods: Forty newly diagnosed cases of Subclinical Hypothyroidism (38 females and 2 males) and age more than 18 years were included. Diagnosis was made on the basis of history, clinical examination and thyroid function tests. Echocardiography was performed in all and was repeated after 4-6 months in those who had diastolic dysfunction. Distribution of Diastolic dysfunction among the involved cases and their response to treatment with L-thyroxine were studied. Results: The diastolic dysfunction was found in 15 (37.5%) and pericardial effusion (PE) in five (12.5%) patients. Fourteen of them had impaired relaxation abnormality and only one patient had pseudonormal pattern. With replacement therapy, 13 reverted back to the normal whereas one having grade 2 diastolic dysfunction (pseudonormal pattern) reverted to grade 1. One patient who had grade 1 diastolic dysfunction (impaired relaxation) did not improve. Pericardial effusion subsided in all 5 cases. Conclusions: Echocardiography may be a useful tool for monitoring the response of diastolic dysfunction to thyroid hormone replacement therapy in patients with Subclinical Hypothyroidism. Our findings suggest that Thyroid Hormone Replacement Therapy may reverse diastolic dysfunction in Subclinical Hypothyroidism. DOI: http://dx.doi.org/10.3126/njh.v11i1.10979   Nepalese Heart Journal 2014;11(1): 33-38


2019 ◽  
Author(s):  
Bolin Wang ◽  
Yan Huang ◽  
Tao Lin

Abstract Background: At present, the relationship between hypothyroidism and the risk of breast cancer is still inconclusive. This meta-analysis was used to systematically assess the relationship between hypothyroidism and breast cancer risk, and to assess whether thyroid hormone replacement therapy can increase breast cancer risk.Methods: The relevant articles about hypothyroidism and the risk of breast cancer were obtained on the electronic database platform. Relevant data were extracted, and odd ratios with corresponding 95% confidence intervals(95% CI) were merged using Stata SE 12.0 software. A total of 19 related studies were included in the meta-analysis, including 6 cohort studies and 13 case-control studies.Result: The results show that hypothyroidism can reduce the risk of breast cancer(odd ratios= 0.90, 95% CI 0.77-1.03), but in Asian populations, patients with hypothyroidism have an increased risk of breast cancer(odd ratios=1.17, 95% CI 0.98-1.35). In addition, patients who received thyroid hormone replacement therapy had a lower risk of developing breast cancer(odd ratios=0.87, 95% CI 0.65-1.09).Conclusion: Hypothyroidism and thyroid hormone replacement therapy reduces the risk of breast cancer, suggesting that low levels of thyroid hormone may be beneficial to breast cancer prevention. Due to the limited number of studies included more large-scale, high-quality, long-term prospective cohort studies are needed.


Sign in / Sign up

Export Citation Format

Share Document